It is, therefore, tempting to speculate that GLP-1 signaling could be harnessed to fight COVID-19 on two levels: secretagogues could prophylactically increase the global population's resilience to the infection, and in acute COVID-19, GLP-1 receptor agonists may be useful in supporting acute therapeutic interventions. This evidence concerns the gene GLP1R and COVID-19.